Liver resectability of advanced liver-limited colorectal liver metastases following mFOLFOX6 with bevacizumab (KSCC0802 Study).

Authors :: Beppu T
Emi Y
Tokunaga S
Oki E
Shirabe K
Ueno S
Kuramoto M
Kabashima A
Takahashi I
Samura H
Eguchi S
Akagi Y
Natsugoe S
Ogata Y
Kakeji Y
Baba H
Maehara Y
Source :: Anticancer research [Anticancer Res] 2014 Nov; Vol. 34 (11), pp. 6655-62.
Publication Year :: 2014
Abstract: Background/aim: The Kyushu Study group of Clinical Cancer (KSCC) conducted phase II trials (KSCC0802-UMIN000001308) concerning liver resectability after first-line treatment of advanced liver-limited colorectal metastases (CRLM) by a prospective, multi-center study.<br />Patients and Methods: Patients received 6 cycles of mFOLFOX6 with bevacizumab followed by evaluating liver resectability. The primary end-point was liver resection rate.<br />Results: The 40 patients enrolled from September 2008 to August 2010. The median number of administration cycles was 6 (range=1-7). The liver resectability cases were 16/40 (40.0 %) and the number of R0 cases was 10 patients (25.0%). An overall response rate was 30.0% (95% CI=15.2%-44.8%). Median progression-free and overall survival of all patients was 9.7 months and 33.0 months), respectively.<br />Conclusion: mFOLFOX6 with bevacizumab regimen is safe and effective for advanced liver-limited CRLM and might lead to high liver resectability.<br /> (Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.)

Tools